This research study is currently not recruiting patients.

? A randomized double-blind placebo-controlled multicenter phase 2 dose-ranging study to assess the safety and efficacy of multiple ianalumab doses administered subcutaneously in patients with moderate to severe primary Sj?gren?s Syndrome



Study Overview

The purpose of the current study is 2-fold: (i) to determine the dose-response relationship of ianalumab for key efficacy and safety parameters in order to define the most appropriate dose(s) for subsequent clinical studies (i.e., phase 3), and (ii) to evaluate which clinical endpoint(s) and/or scoring systems best characterize the multidimensional features of pSS.


Study Description

The purpose of the current study is 2-fold: (i) to determine the dose-response relationship of ianalumab for key efficacy and safety parameters in order to define the most appropriate dose(s) for subsequent clinical studies (i.e., phase 3), and (ii) to evaluate which clinical endpoint(s) and/or scoring systems best characterize the multidimensional features of pSS.

Research Study Identifier: TX9270
ClinicalTrials.gov Identifier: NCT1705730623
Principal Investigator: Domenick Zero, DDS, MS


Not Recruiting

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.